Published in Proc Natl Acad Sci U S A on July 07, 2006
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A (2008) 3.83
Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer (2007) 3.57
Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics (2008) 1.95
Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol (2008) 1.62
Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer Res (2010) 1.54
mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol (2011) 1.40
Loss-of-function mutations in RAB18 cause Warburg micro syndrome. Am J Hum Genet (2011) 1.36
Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol (2008) 1.30
Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS One (2013) 1.29
Cancer biomarker discovery: the entropic hallmark. PLoS One (2010) 1.26
Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy. Am J Pathol (2011) 1.24
Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC Cancer (2010) 1.16
Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes. BMC Cancer (2009) 1.15
Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence. J Am Med Inform Assoc (2011) 1.12
Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res (2010) 1.09
Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells. Prostate (2009) 1.08
Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol (2007) 1.08
Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. Cancer Res (2010) 1.07
The genomic landscape of prostate cancer. Front Endocrinol (Lausanne) (2012) 1.07
LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer. BMC Med Genomics (2010) 1.04
β4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest (2013) 1.03
Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. Differentiation (2008) 1.03
Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer. Mol Cancer (2009) 1.02
Molecular pathways and targets in prostate cancer. Oncotarget (2014) 1.00
Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection. BMC Cancer (2010) 1.00
Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer (2007) 0.98
Notch signaling in prostate cancer: a moving target. Prostate (2014) 0.98
Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer (2014) 0.98
The wisdom of the commons: ensemble tree classifiers for prostate cancer prognosis. Bioinformatics (2008) 0.97
Whole-lesion apparent diffusion coefficient metrics as a marker of percentage Gleason 4 component within Gleason 7 prostate cancer at radical prostatectomy. J Magn Reson Imaging (2014) 0.97
Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis. J Clin Invest (2014) 0.96
A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR. PLoS One (2008) 0.94
PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality. Mol Cancer Res (2013) 0.92
Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine. Proc Natl Acad Sci U S A (2007) 0.92
The significance of monoamine oxidase-A expression in high grade prostate cancer. J Urol (2008) 0.92
Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics (2009) 0.90
Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. Cancer Res (2009) 0.90
Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer. Proteomics Clin Appl (2011) 0.89
Management of low risk prostate cancer-active surveillance and focal therapy. Nat Rev Clin Oncol (2014) 0.88
Targeting monoamine oxidase A in advanced prostate cancer. J Cancer Res Clin Oncol (2010) 0.88
A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression. J Biol Chem (2012) 0.86
Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3. Pharmacogenomics J (2012) 0.86
The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions. Br J Cancer (2006) 0.84
Reduced glycosylation of α-dystroglycans on carcinoma cells contributes to formation of highly infiltrative histological patterns in prostate cancer. Prostate (2011) 0.84
Prostate cancer-associated gene expression alterations determined from needle biopsies. Clin Cancer Res (2009) 0.83
Evaluation of ERG responsive proteome in prostate cancer. Prostate (2013) 0.83
Restoration of compact Golgi morphology in advanced prostate cancer enhances susceptibility to galectin-1-induced apoptosis by modifying mucin O-glycan synthesis. Mol Cancer Res (2014) 0.83
Transforming Growth Factor-{beta}-Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition. Clin Cancer Res (2009) 0.83
The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making. Biomed Res Int (2014) 0.83
Active surveillance and focal therapy for low-intermediate risk prostate cancer. Transl Androl Urol (2015) 0.82
Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts. Oncotarget (2015) 0.80
Merkel cell polyomavirus is not detected in prostate cancers, surrounding stroma, or benign prostate controls. J Clin Virol (2009) 0.80
Rab proteins and the secretory pathway: the case of rab18 in neuroendocrine cells. Front Endocrinol (Lausanne) (2011) 0.80
The monoamine oxidase A gene promoter repeat and prostate cancer risk. Prostate (2012) 0.79
Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development? J Cancer Res Clin Oncol (2015) 0.78
Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. PLoS One (2012) 0.78
Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. Neoplasia (2016) 0.77
Comparison of expression pattern of monoamine oxidase A with histopathologic subtypes and tumour grade of renal cell carcinoma. Med Sci Monit (2012) 0.77
Molecular characterization of Gleason patterns 3 and 4 prostate cancer using reverse Warburg effect-associated genes. Cancer Metab (2016) 0.77
Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. World J Urol (2015) 0.77
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes. PLoS One (2014) 0.76
Does true Gleason pattern 3 merit its cancer descriptor? Nat Rev Urol (2016) 0.76
Molecular profiling of prostatic acinar morphogenesis identifies PDCD4 and KLF6 as tissue architecture-specific prognostic markers in prostate cancer. Am J Pathol (2012) 0.75
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. Oncoimmunology (2016) 0.75
PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER. Expert Rev Precis Med Drug Dev (2016) 0.75
MAOA-a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells. Sci Rep (2017) 0.75
Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer. Br J Cancer (2015) 0.75
An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma. Int J Genomics (2015) 0.75
Re: A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Eur Urol (2007) 0.75
Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. Clin Cancer Res (2017) 0.75
Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort. Oncotarget (2017) 0.75
Monoamine Oxidase A is Highly Expressed in Classical Hodgkin Lymphoma. J Pathol (2017) 0.75
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A (2002) 30.32
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol (2005) 12.31
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 10.99
Principal components analysis to summarize microarray experiments: application to sporulation time series. Pac Symp Biocomput (2000) 5.83
Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol (1974) 5.26
Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst (2005) 5.10
Redox redux: revisiting PTPs and the control of cell signaling. Cell (2005) 5.10
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69
Long-term survival among men with conservatively treated localized prostate cancer. JAMA (1995) 4.24
Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res (2001) 3.45
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology (2000) 2.35
SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene (2003) 2.32
Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol (2001) 2.31
Role of stroma in carcinogenesis of the prostate. Differentiation (2002) 2.26
Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol (2000) 2.19
Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res (2003) 2.08
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene (2005) 1.89
Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res (2003) 1.83
Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res (2004) 1.77
Neuroendocrine differentiation in prostatic carcinoma. Prostate (1999) 1.74
Peroxiredoxins in breast carcinoma. Clin Cancer Res (2003) 1.59
Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene (2000) 1.57
Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer (2003) 1.47
YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate (2004) 1.40
Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate (2005) 1.38
Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate (2003) 1.26
Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer (2002) 1.15
Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer (1998) 1.13
Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol (1996) 1.11
Characterization of a novel type of human microsomal 3alpha -hydroxysteroid dehydrogenase: unique tissue distribution and catalytic properties. J Biol Chem (2001) 1.02
Digital expression profiles of the prostate androgen-response program. J Steroid Biochem Mol Biol (2002) 0.98
Amine oxidases and tumors. Neurotoxicology (2004) 0.96
Amplification and overexpression of Elongin C gene discovered in prostate cancer by cDNA microarrays. Lab Invest (2002) 0.94
Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. Eur Urol (2005) 0.86
Expression and immunolocalisation of neutral endopeptidase in prostate cancer. Eur Urol (2003) 0.84
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
Integration of biological networks and gene expression data using Cytoscape. Nat Protoc (2007) 27.10
Whole-genome shotgun assembly and analysis of the genome of Fugu rubripes. Science (2002) 20.59
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science (2010) 18.45
Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol (2008) 15.90
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol (2008) 11.43
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
A genomic regulatory network for development. Science (2002) 9.67
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A (2002) 5.98
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
The Inferelator: an algorithm for learning parsimonious regulatory networks from systems-biology data sets de novo. Genome Biol (2006) 5.22
Coordinate regulation of energy transduction modules in Halobacterium sp. analyzed by a global systems approach. Proc Natl Acad Sci U S A (2002) 4.96
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood. Nat Biotechnol (2008) 4.40
PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet (2007) 4.09
Complementary profiling of gene expression at the transcriptome and proteome levels in Saccharomyces cerevisiae. Mol Cell Proteomics (2002) 3.89
Systems medicine: the future of medical genomics and healthcare. Genome Med (2009) 3.85
A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A (2008) 3.83
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54
Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res (2004) 3.46
A predictive model for transcriptional control of physiology in a free living cell. Cell (2007) 3.35
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med (2012) 3.21
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res (2007) 3.08
The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res (2006) 3.07
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
A data integration methodology for systems biology. Proc Natl Acad Sci U S A (2005) 2.93
How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol (2004) 2.92
A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol (2011) 2.91
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One (2011) 2.88
Quantitative phosphoproteome analysis using a dendrimer conjugation chemistry and tandem mass spectrometry. Nat Methods (2005) 2.87
Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell (2011) 2.86
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res (2011) 2.81
Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer (2005) 2.79
Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci U S A (2009) 2.76
Genome sequence of Haloarcula marismortui: a halophilic archaeon from the Dead Sea. Genome Res (2004) 2.75
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res (2006) 2.69
Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab (2006) 2.57
Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. J Clin Oncol (2006) 2.56
Extracellular microRNA: a new source of biomarkers. Mutat Res (2011) 2.55
Analysis of the human neurexin genes: alternative splicing and the generation of protein diversity. Genomics (2002) 2.54
The value of sharing treatment decision making with patients: expecting too much? JAMA (2013) 2.48
HIF induces human embryonic stem cell markers in cancer cells. Cancer Res (2011) 2.46
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res (2010) 2.42
Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A (2007) 2.38
LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate (2003) 2.28
A provisional regulatory gene network for specification of endomesoderm in the sea urchin embryo. Dev Biol (2002) 2.26
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer (2005) 2.25
Regulatory gene networks and the properties of the developmental process. Proc Natl Acad Sci U S A (2003) 2.24
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res (2014) 2.15
Hematopoietic stem cells contribute to the regeneration of renal tubules after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol (2003) 2.12
Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry (2007) 2.11
Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice. Clin Cancer Res (2004) 2.07
Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. J Natl Cancer Inst (2004) 2.06
The quality of quality measurement in U.S. nursing homes. Gerontologist (2003) 2.04
The DNA sequence and analysis of human chromosome 14. Nature (2003) 2.02
Supervised normalization of microarrays. Bioinformatics (2010) 2.00
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol (2006) 1.98
Bayesian network approach to cell signaling pathway modeling. Sci STKE (2002) 1.96
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet (2005) 1.96
Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics (2008) 1.95
An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry (2008) 1.94
Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One (2008) 1.93
Statins and prostate cancer risk: a case-control study. Am J Epidemiol (2005) 1.90
Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes (2002) 1.89
Improved detection of prostate cancer using classification and regression tree analysis. J Clin Oncol (2005) 1.85
Patterns and correlates of patient referral to surgeons for treatment of breast cancer. J Clin Oncol (2007) 1.84
Collaborative clinical quality improvement for pressure ulcers in nursing homes. J Am Geriatr Soc (2007) 1.82
In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res (2005) 1.82
The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis. BMC Genomics (2011) 1.79
Cancer micrometastasis and tumour dormancy. APMIS (2008) 1.78